Dr. Ahmed Abdalla
Claim this profileUniversity of South Alabama Mitchell Cancer Institute
Studies Cancer
Studies Ovarian Cancer
7 reported clinical trials
28 drugs studied
Area of expertise
1Cancer
KRAS positive
BRAF positive
NRAS positive
2Ovarian Cancer
KRAS positive
BRAF positive
NRAS positive
Affiliated Hospitals
Clinical Trials Ahmed Abdalla is currently running
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
Palbociclib + Binimetinib
for Pancreatic Cancer
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Recruiting1 award Phase 210 criteria
More about Ahmed Abdalla
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Ahmed Abdalla has experience with
- Binimetinib
- Oxaliplatin
- Palbociclib
- Fluorouracil
- Ipatasertib
- Paclitaxel
Breakdown of trials Ahmed Abdalla has run
Cancer
Ovarian Cancer
Relapse
Solid Tumors
Gynecologic Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ahmed Abdalla specialize in?
Ahmed Abdalla focuses on Cancer and Ovarian Cancer. In particular, much of their work with Cancer has involved KRAS positive patients, or patients who are BRAF positive.
Is Ahmed Abdalla currently recruiting for clinical trials?
Yes, Ahmed Abdalla is currently recruiting for 7 clinical trials in Mobile Alabama. If you're interested in participating, you should apply.
Are there any treatments that Ahmed Abdalla has studied deeply?
Yes, Ahmed Abdalla has studied treatments such as Binimetinib, Oxaliplatin, Palbociclib.
What is the best way to schedule an appointment with Ahmed Abdalla?
Apply for one of the trials that Ahmed Abdalla is conducting.
What is the office address of Ahmed Abdalla?
The office of Ahmed Abdalla is located at: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama 36688 United States. This is the address for their practice at the University of South Alabama Mitchell Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.